261 related articles for article (PubMed ID: 26429698)
1. Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease.
McRae BL; Levin AD; Wildenberg ME; Koelink PJ; Bousquet P; Mikaelian I; Sterman AS; Bryant S; D'Haens G; Kamath R; Salfeld J; van den Brink GR
J Crohns Colitis; 2016 Jan; 10(1):69-76. PubMed ID: 26429698
[TBL] [Abstract][Full Text] [Related]
2. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
West NR; Hegazy AN; Owens BMJ; Bullers SJ; Linggi B; Buonocore S; Coccia M; Görtz D; This S; Stockenhuber K; Pott J; Friedrich M; Ryzhakov G; Baribaud F; Brodmerkel C; Cieluch C; Rahman N; Müller-Newen G; Owens RJ; Kühl AA; Maloy KJ; Plevy SE; ; Keshav S; Travis SPL; Powrie F
Nat Med; 2017 May; 23(5):579-589. PubMed ID: 28368383
[TBL] [Abstract][Full Text] [Related]
3. Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-α and IL-23p19 bioactivities.
Wang J; Kang G; Lu H; de Marco A; Yuan H; Feng Z; Gao M; Wang X; Wang H; Zhang X; Wang Y; Zhang M; Wang P; Feng Y; Liu Z; Cao X; Huang H
Clin Transl Med; 2024 Mar; 14(3):e1636. PubMed ID: 38533646
[TBL] [Abstract][Full Text] [Related]
4. TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis.
Solitano V; Jairath V; Ungaro F; Peyrin-Biroulet L; Danese S
Med; 2024 May; 5(5):386-400. PubMed ID: 38574740
[TBL] [Abstract][Full Text] [Related]
5. Novel treatments for inflammatory bowel disease.
Lee HS; Park SK; Park DI
Korean J Intern Med; 2018 Jan; 33(1):20-27. PubMed ID: 29223139
[TBL] [Abstract][Full Text] [Related]
6. Predictive biomarkers for anti-TNF alpha therapy in IBD patients.
Kumar M; Murugesan S; Ibrahim N; Elawad M; Al Khodor S
J Transl Med; 2024 Mar; 22(1):284. PubMed ID: 38493113
[TBL] [Abstract][Full Text] [Related]
7. Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn's Disease.
Tubau-Juni N; Hontecillas R; Leber AJ; Alva SS; Bassaganya-Riera J
Inflamm Bowel Dis; 2024 Apr; 30(4):671-680. PubMed ID: 37934790
[TBL] [Abstract][Full Text] [Related]
8. An anti-TNF-glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases.
McPherson MJ; Hobson AD; Hernandez A; Marvin CC; Waegell W; Goess C; Oh JZ; Shi D; Hayes ME; Wang L; Wang L; Schmidt D; Wang Z; Pitney V; McCarthy K; Jia Y; Wang C; Kang BN; Bryant S; Mathieu S; Ruzek M; Parmentier J; D'Cunha RR; Pang Y; Phillips L; Brown NJ; Xu J; Graff C; Tian Y; Longenecker KL; Qiu W; Zhu H; Liu W; Zheng P; Bi Y; Stoffel R
Sci Transl Med; 2024 Mar; 16(739):eadd8936. PubMed ID: 38507467
[TBL] [Abstract][Full Text] [Related]
9. Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease.
Gonzalez-Rey E; Varela N; Sheibanie AF; Chorny A; Ganea D; Delgado M
Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4228-33. PubMed ID: 16537513
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease.
Lindebo Holm T; Poulsen SS; Markholst H; Reedtz-Runge S
Int J Inflam; 2012; 2012():412178. PubMed ID: 22536543
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis.
Alivernini S; Pugliese D; Tolusso B; Bui L; Petricca L; Guidi L; Mirone L; Rapaccini GL; Federico F; Ferraccioli G; Armuzzi A; Gremese E
RMD Open; 2018; 4(1):e000667. PubMed ID: 29657833
[TBL] [Abstract][Full Text] [Related]
12. A personalized network framework reveals predictive axis of anti-TNF response across diseases.
Gerassy-Vainberg S; Starosvetsky E; Gaujoux R; Blatt A; Maimon N; Gorelik Y; Pressman S; Alpert A; Bar-Yoseph H; Dubovik T; Perets B; Katz A; Milman N; Segev M; Chowers Y; Shen-Orr SS
Cell Rep Med; 2024 Jan; 5(1):101300. PubMed ID: 38118442
[TBL] [Abstract][Full Text] [Related]
13. What is wrong with granulocytes in inflammatory bowel diseases?
Levine AP; Segal AW
Dig Dis; 2013; 31(3-4):321-7. PubMed ID: 24246982
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF Alpha Antibody Humira with pH-dependent Binding Characteristics: A constant-pH Molecular Dynamics, Gaussian Accelerated Molecular Dynamics, and In Vitro Study.
Hong ST; Su YC; Wang YJ; Cheng TL; Wang YT
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33672169
[TBL] [Abstract][Full Text] [Related]
15. Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy.
Martin JC; Chang C; Boschetti G; Ungaro R; Giri M; Grout JA; Gettler K; Chuang LS; Nayar S; Greenstein AJ; Dubinsky M; Walker L; Leader A; Fine JS; Whitehurst CE; Mbow ML; Kugathasan S; Denson LA; Hyams JS; Friedman JR; Desai PT; Ko HM; Laface I; Akturk G; Schadt EE; Salmon H; Gnjatic S; Rahman AH; Merad M; Cho JH; Kenigsberg E
Cell; 2019 Sep; 178(6):1493-1508.e20. PubMed ID: 31474370
[TBL] [Abstract][Full Text] [Related]
16. Engaging natural antibody responses for the treatment of inflammatory bowel disease via phosphorylcholine-presenting nanofibres.
Curvino EJ; Roe EF; Freire Haddad H; Anderson AR; Woodruff ME; Votaw NL; Segura T; Hale LP; Collier JH
Nat Biomed Eng; 2024 May; 8(5):628-649. PubMed ID: 38012308
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF therapy and immunogenicity in inflammatory bowel diseases: a translational approach.
Genaro LM; Gomes LEM; Franceschini APMF; Ceccato HD; de Jesus RN; Lima AP; Nagasako CK; Fagundes JJ; Ayrizono MLS; Leal RF
Am J Transl Res; 2021; 13(12):13916-13930. PubMed ID: 35035733
[TBL] [Abstract][Full Text] [Related]
18. Targeting B cells for inflammatory bowel disease treatment: back to the future.
Castro-Dopico T; Colombel JF; Mehandru S
Curr Opin Pharmacol; 2020 Dec; 55():90-98. PubMed ID: 33166872
[TBL] [Abstract][Full Text] [Related]
19. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease.
Kopylov U; Seidman E
Therap Adv Gastroenterol; 2016 Jul; 9(4):513-26. PubMed ID: 27366220
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-18 Inhibition in Inflammatory Bowel Disease: A Delicate Balance.
Geertsema S; Fagundes RR; Otten AT; Dijkstra G; Faber KN; Bourgonje AR
Inflamm Bowel Dis; 2024 Apr; 30(4):693-694. PubMed ID: 38442894
[No Abstract] [Full Text] [Related]
[Next] [New Search]
